() Historical III-3 1,069 Aim: To investigate how the introduction of In pre-cfDNA and in years 1 and 2 after the control cfDNA testing influenced women's testing introduction of cfDNA, 306, 362 and 401 choices following a positive trisomy 21 women who screened positive were seen, screening. respectively. Setting: Hong Kong In year 1 and year 2, 12.6 and 26.7% of women underwent cfDNA while IPD was Population: Women (largely Chinese) with a decreased by 16.3 and 25.6%, respectively singleton pregnancy and a positive trisomy (p<0.001). Both chorionic villus sampling and 21 screening (first trimester combined screen amniocentesis decreased in year 1, but only or second trimester screening depending on the former in year 2. The rate of declining gestational age at presentation). further testing was similar before and after Methods: With the use of descriptive statistics introduction of cfDNA (p = 0.213). and a test, rates of women choosing the χ2 invasive test and those who declined further testing were compared before and after the introduction of CFDNA TESTING. We also compared demographic factors with rates of different options including an invasive test, cfDNA or further testing’. ‘declined Predictors of accepting cfDNA and an invasive test were analyzed with multiple logistic regression. Conventional screening was funded publicly, but cfDNA was not. Outcomes: differences in the uptake rates of invasive prenatal diagnosis (IPD) or no testing before and after the introduction of cfDNA and factors affecting choices.
() Historical control III-3 1,069 Aim: To investigate how the introduction of cfDNA testing influenced women's testing choices following a positive trisomy 21 screening. Setting: Hong Kong Population: Women (largely Chinese) with a singleton pregnancy and a positive trisomy 21 screening (first trimester combined screen or second trimester screening depending on gestational age at presentation). Methods: With the use of descriptive statistics and a χ2 test, rates of women choosing the invasive test and those who declined further testing were compared before and after the introduction of CFDNA TESTING. We also compared demographic factors with rates of different options including an invasive test, cfDNA or ‘declined further testing’. Predictors of accepting cfDNA and an invasive test were analyzed with multiple logistic regression. Conventional screening was funded publicly, but cfDNA was not. Outcomes: differences in the uptake rates of invasive prenatal diagnosis (IPD) or no testing before and after the introduction of cfDNA and factors affecting choices. In pre-cfDNA and in years 1 and 2 after the introduction of cfDNA, 306, 362 and 401 women who screened positive were seen, respectively. In year 1 and year 2, 12.6 and 26.7% of women underwent cfDNA while IPD was decreased by 16.3 and 25.6%, respectively (p<0.001). Both chorionic villus sampling and amniocentesis decreased in year 1, but only the former in year 2. The rate of declining further testing was similar before and after introduction of cfDNA (p = 0.213).